RESCEU

Respiratory syncytial virus consortium in Europe
RESCEU logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 6
Grant agreement number
116019

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
14 498 125
EFPIA in kind
14 673 665
Total Cost
29 171 790

Summary

Respiratory syncytial virus (RSV) is not well known outside medical circles, yet most people have probably suffered from it in childhood, as it is the most common cause of severe respiratory illness in infants and children worldwide. The elderly and people with weakened immune systems are also vulnerable to RSV infection. While most people’s symptoms are mild, it can result in pneumonia and 3.4 million cases annually require hospitalisation. There is no specific treatment or vaccine for RSV. The goal of the RESCEU project is to gather information on the scale of RSV infection in Europe and its economic impacts. It will then use this information to design best practice guidelines to improve the way RSV cases are monitored in Europe, and to shape future vaccination programmes. The team will also gather and analyse patient samples to identify biological markers associated with severe RSV infection. This information could aid in diagnosis and facilitate the development of new treatments and vaccines.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • GlaxoSmithKline Biologicals, Rixensart, Belgium
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novavax Inc, Gaithersburg, United States
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi Pasteur SA, Lyon, France
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Servizo Galego De Saude, Santiago de Compostela, Spain
  • Statens Serum Institut, Copenhagen S, Denmark
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universiteit Antwerpen, Antwerp, Belgium
  • University of Oxford, Oxford, United Kingdom
  • Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma, Turku, Finland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Synapse Research Management Partners SL, Barcelona, Spain

CONTACT

Project coordinator
Alan KENNEDY
THE UNIVERSITY OF EDINBURGH
alan.kennedy[at]ed.ac.uk
Project leader
Judith Hackett
AstraZeneca
Judith.Hackett[at]astrazeneca.com
Project contact
info[at]resc-eu.org